Skip to main content

Table 1 Clinicopathological characteristics of synovial tissues obtained by surgical biopsy and ultrasound-guided biopsy

From: Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure

Biopsy Age (years) Sex Disease duration (years) RF/aCCP Disease-modifying antirheumatic drugs Joint Valid samples/total samples Valid sections Cumulative area (mm2)
S-SY1 65 Female 18 +/+ MTX Wrist 3/3 9 24.47
S-SY2 44 Female 12 -/- PDN I MTP 3/3 9 37.72
S-SY3 63 Female 14 +/+ MTX + HCQ II and III MTPs 3/3 9 44.02
S-SY4 46 Female 34 -/+ HCQ Wrist 4/4 12 41.68
S-SY5 46 Female 17 -/- LFN + PDN Wrist 5/5 15 60.32
S-SY6 75 Female 7 -/- MTX + PDN MCPs 3/3 9 34.75
S-SY7 78 Female 8 -/- MTX + PDN MCPs 3/3 9 38.68
S-SY8 46 Male 2 -/+ MTX + PDN MCPs 3/3 9 22.42
S-SY9 68 Female 5 -/- MTX + HCQ + PDN I MTP 3/3 9 45.01
U-SY1 23 Female 5 +/+ CYA + PDN II MCP 4/8 12 16.86
U-SY2 59 Female 4 -/- MTX + PDN V MCP 5/8 15 17.64
U-SY3 64 Female 18 +/+ PDN II PIP 10/12 30 38.28
U-SY4 61 Female 11 -/+ MTX + PDN V MCP 3/12 9 7.29
U-SY5 69 Male 10 +/+ MTX + HCQ + PDN II MCP 8/12 24 20.16
U-SY6 75 Male 11 +/+ HCQ + SLZ + PDN V MCP 10/12 29 28.71
U-SY7 67 Female 7 -/+ MTX + HCQ + PDN II MCP 8/12 23 8.82
U-SY8 62 Female 8 -/- MTX + PDN II MCP 7/12 20 8.43
U-SY9 61 Female 11 +/+ MTX + HCQ + PDN II MCP 9/12 26 20.91
  1. The good quality/overall number of collected sample rate and the number of valid sections obtained considering three different cutting levels are provided. The cumulative area is computed on overall sections for each patient. S-SY, surgical biopsy synovial tissue; U-SY, ultrasound-guided biopsy synovial tissue; RF/aCCP, rheumatoid factor/anticyclic citrullinated peptide antibodies; MTX, methotrexate: PDN, prednisone; HCQ, hydroxychloroquine; LFN, leflunomide; CYA, cyclosporine A; SLZ, sulfasalazine; MCP, metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal interphalangeal.